Janux Therapeutics — Third Quarter 2026 Earnings Summary

Janux Therapeutics reported a net loss of $21.6 million for the third quarter ended September 30, 2026, with research and development expenses totaling $30.6 million. The company maintains a strong balance sheet with $945.7 million in cash, cash equivalents, and short-term investments to support its clinical programs. Key operational updates include the dosing of the first patient in a Phase 1 study combining JANX013 with JANX007 and the continued enrollment of patients in the JANX014 Phase 1 trial for metastatic castration-resistant prostate cancer. Initial clinical data from the Phase 1 healthy-volunteer study of JANX011 is scheduled to be presented during an investor webcast on November 9, 2026.